Cancer Screening After 40: Breast, Colorectal, Cervical, Liver, and What Not to Overcheck

After age forty, “cancer screening” should not mean testing for everything at once, nor should it mean waiting for symptoms before asking. This evidence bundle shows that each cancer type has its own age range, screening method, and risk group, especially when Thailand’s screening context is considered.

This article summarizes only what appears in the research bundle: breast, colorectal, cervical, liver, and selected bile duct context. The goal is to help you have a clearer conversation with a doctor or health service, not to replace personal medical advice.

Three-Line Summary

1. Clinical guidelines recommend that average-risk women start breast cancer screening with mammography at age 40, either annually or every two years, but evidence on the best interval specifically for Thai women is limited.
2. Major international guidelines recommend colorectal cancer screening from age 45, while Thailand’s national program uses biennial FIT from age 50, followed by colonoscopy when FIT is positive.
3. Current cervical screening guidance supports primary hrHPV DNA testing every 5 years for women aged 30-60, while liver cancer surveillance is for high-risk groups, not all adults 40+.

Start With Risk, Not Every Test at Once

The overall evidence for this topic is labeled strong because breast, colorectal, and cervical cancer screening guidance is supported by major clinical practice guidelines and evidence from large randomized trials or large cohort studies.

But strong evidence does not mean everyone should be tested for everything on the same day. In this bundle, liver cancer evidence is restricted to high-risk groups, such as people with cirrhosis or chronic hepatitis B or C infection. Universal screening for liver fluke-associated cholangiocarcinoma in the general 40+ population remains unproven.

For adults 40+, the safest takeaway is to screen according to age, sex, risk, and health-system context, not according to fear or a screening package alone.

Breast: Discuss Mammography From Age 40

Clinical practice guidelines recommend that average-risk women start breast cancer screening with mammography at age 40, either annually or biennially, to reduce breast cancer mortality.

The bundle also states that evidence is limited on the optimal screening interval specifically for Thai women. So the question to bring to a doctor is not only “Should I screen?” but also “How often does screening make sense in my context?”

⚠️ Caveat: this article does not specify advice for people at especially high risk, because the bundle mainly addresses average-risk women. If you have a family history or a specific risk factor, consult a doctor directly.

Colorectal: International Age 45, Thailand FIT From 50

Major international guidelines recommend starting colorectal cancer screening at age 45. Thailand’s national screening program uses a two-step approach beginning at age 50: fecal immunochemical testing, or FIT, every two years, followed by colonoscopy when FIT is positive.

This is because endoscopy resources in Thailand are limited. FIT works as a first step that helps identify who should go on to colonoscopy.

Just don’t read FIT as a replacement for colonoscopy in every situation. The bundle does not say that. Here, colonoscopy is the follow-up test after a positive FIT within Thailand’s screening program.

Cervical: hrHPV DNA Is Central From Age 30 to 60

Thailand’s national cervical cancer screening program historically began at age 30 using cytology. Current guidance supports primary high-risk human papillomavirus, or hrHPV, DNA testing every 5 years for women aged 30-60.

If you are 40+, cervical screening is not simply a question of whether you were tested once. It also matters which test was used, what age range you are in, and whether your prior results are documented.

⚠️ Caveat: the bundle says evidence is limited on the cost-effectiveness of continuing routine screening in average-risk women beyond age 65 when prior negative results are documented. Do not use this article alone to decide whether to stop or continue screening.

Liver and Bile Duct: Surveillance Only for High-Risk Groups

The guideline evidence in this bundle recommends hepatocellular carcinoma surveillance with abdominal ultrasound and alpha-fetoprotein every six months for high-risk individuals, such as people with cirrhosis or chronic hepatitis B or C infection.

Keep this separate from “everyone should check the liver.” The evidence does not say that the same approach should be used for the general 40+ population.

For cholangiocarcinoma associated with liver fluke exposure, the bundle states that universal screening for the general 40+ population remains unproven. This should be read as an area where evidence is not strong enough for a broad recommendation.

Reading the Evidence Without Overclaiming

Topic	What the bundle says	Confidence for you
Breast cancer	Average-risk women start mammography at age 40, annually or every two years, to reduce mortality	Strong within guideline framing, but the best interval for Thai women remains limited
Colorectal cancer	International guidance starts at age 45; Thailand starts biennial FIT at age 50, with colonoscopy when positive	Strong for the screening principle, with clear Thai context
Cervical cancer	Primary hrHPV DNA testing every 5 years is supported for women aged 30-60	Strong for this age range
Beyond age 65	Cost-effectiveness evidence is limited for continued routine screening in average-risk women with documented prior negative results	Limited
Liver cancer	Ultrasound and alpha-fetoprotein every 6 months are for high-risk groups such as cirrhosis or chronic hepatitis B/C	Strong only for high-risk groups
Bile duct cancer	Universal screening for the general 40+ population remains unproven	Limited

The accurate message is not “the more testing, the better.” It is “screen the right person, at the right age, for the right risk, with a plan for follow-up.”

How to Talk With a Doctor

If you are 40 or older, start by asking whether you are in an average-risk group or have a specific risk factor. Then discuss screening based on sex, age, health history, and the health services available to you.

Practical questions include: whether to begin breast screening and at what interval, whether colorectal screening should use FIT or when colonoscopy is needed, whether your last cervical screening used cytology or hrHPV DNA testing, and whether you have a liver-related reason to enter six-month surveillance.

Do not buy a cancer screening package or interpret results by yourself based on this article, especially if you have chronic liver disease, a prior abnormal result, or a specific risk factor. Consult the doctor or health professional who cares for you.

This article is for understanding, not personal medical advice. Screening choices, result interpretation, and follow-up should be done with the doctor or health service that cares for you.